Sarepta Therapeutics Stock Probability of Future Stock Price Finishing Under 104.98

SRPT Stock  USD 110.50  0.36  0.32%   
Sarepta Therapeutics' future price is the expected price of Sarepta Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Sarepta Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Sarepta Therapeutics Backtesting, Sarepta Therapeutics Valuation, Sarepta Therapeutics Correlation, Sarepta Therapeutics Hype Analysis, Sarepta Therapeutics Volatility, Sarepta Therapeutics History as well as Sarepta Therapeutics Performance.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.
  
Price Earnings To Growth Ratio is likely to gain to 0.63 in 2024, whereas Price To Sales Ratio is likely to drop 6.81 in 2024. Please specify Sarepta Therapeutics' target price for which you would like Sarepta Therapeutics odds to be computed.

Sarepta Therapeutics Target Price Odds to finish below 104.98

The tendency of Sarepta Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 104.98  or more in 90 days
 110.50 90 days 104.98 
near 1
Based on a normal probability distribution, the odds of Sarepta Therapeutics to drop to $ 104.98  or more in 90 days from now is near 1 (This Sarepta Therapeutics probability density function shows the probability of Sarepta Stock to fall within a particular range of prices over 90 days) . Probability of Sarepta Therapeutics price to stay between $ 104.98  and its current price of $110.5 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days Sarepta Therapeutics has a beta of 0.73. This usually implies as returns on the market go up, Sarepta Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Sarepta Therapeutics will be expected to be much smaller as well. Additionally Sarepta Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Sarepta Therapeutics Price Density   
       Price  

Predictive Modules for Sarepta Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sarepta Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
108.69110.50112.31
Details
Intrinsic
Valuation
LowRealHigh
95.3897.19121.55
Details
Naive
Forecast
LowNextHigh
105.49107.30109.11
Details
22 Analysts
Consensus
LowTargetHigh
164.36180.61200.48
Details

Sarepta Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Sarepta Therapeutics is not an exception. The market had few large corrections towards the Sarepta Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sarepta Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sarepta Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.46
β
Beta against Dow Jones0.73
σ
Overall volatility
8.52
Ir
Information ratio -0.27

Sarepta Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sarepta Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sarepta Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sarepta Therapeutics generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 1.24 B. Net Loss for the year was (535.98 M) with loss before overhead, payroll, taxes, and interest of (78.07 M).
Sarepta Therapeutics currently holds about 2.07 B in cash with (500.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Over 92.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Sarepta stock outlook strong, says Piper, as rivals show early-stage DMD data

Sarepta Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sarepta Stock often depends not only on the future outlook of the current and potential Sarepta Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sarepta Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding92.4 M
Cash And Short Term Investments1.7 B

Sarepta Therapeutics Technical Analysis

Sarepta Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Sarepta Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Sarepta Therapeutics. In general, you should focus on analyzing Sarepta Stock price patterns and their correlations with different microeconomic environments and drivers.

Sarepta Therapeutics Predictive Forecast Models

Sarepta Therapeutics' time-series forecasting models is one of many Sarepta Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Sarepta Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Sarepta Therapeutics

Checking the ongoing alerts about Sarepta Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Sarepta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sarepta Therapeutics generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 1.24 B. Net Loss for the year was (535.98 M) with loss before overhead, payroll, taxes, and interest of (78.07 M).
Sarepta Therapeutics currently holds about 2.07 B in cash with (500.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Over 92.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Sarepta stock outlook strong, says Piper, as rivals show early-stage DMD data

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.